Most Read Articles
Dr. Joseph Delano Fule Robles, 07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

Roshini Claire Anthony, 13 May 2019

Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.

Cognitive behavioural strategies yield modest reductions in symptoms in advanced cancer

14 Sep 2018
Singling out the DNA of HPV as a routine test proven to significantly locate pre-cancerous lesions

Cognitive behavioural strategies (CBS) may provide only small therapeutic relief for advanced cancer patients receiving treatment and experiencing co-occurring pain, sleep disturbance and fatigue, a recent study has found.

Researchers enrolled 164 advanced cancer patients who were undergoing chemotherapy. Participants randomly received a CBS intervention (n=85; mean age 58.44±9.89 years; 72 percent female), involving nature imagery and relaxation exercises, or cancer education (n=79; mean age 58.61±9.03 years; 75 percent female), which included recordings of educational materials.

Groups demonstrated statistically comparable symptom cluster severity scores at follow-up weeks 3, 6 and 9. The same was true for symptom cluster scores for interference with daily life. In terms of symptom cluster distress, the CBS group showed significantly lower mean scores at week 6 (1.82 vs 2.15; p=0.04), but scores were similar at weeks 3 and 9.

In comparison, user perception was better for the CBS intervention, which more participants enjoyed than the cancer education control (67 percent vs 36 percent). Similarly, more participants in the CBS group reported perceived improvement in symptoms (65 percent vs 18 percent) and felt greater control over their symptoms (46 percent vs 24 percent).

“The CBS intervention may provide some small therapeutic benefit for patients experiencing co-occurring pain, fatigue and sleep disturbance. Clinicians can encourage self-management of this symptom cluster by identifying strategies that reduce stress, enhance positive expectations and foster perceptions of personal control over symptoms,” said researchers.

Future studies should focus on the development of effective interventions and strategies that may help relieve the burden of co-occurring symptoms, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

Roshini Claire Anthony, 13 May 2019

Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.